Many effective active pharmaceutical ingredients reach the target tissue only in limited concentrations and may therefore cause undesirable side effects. InnoMedica’s proprietary nanotechnology combines these active substances with a liposomal nanocarrier to precisely control their distribution within the body.
Through a proprietary manufacturing process, InnoMedica’s nanocarriers are particularly small, uniform and highly stable. They are composed of natural lipids and are designed to mimic the body’s own transport mechanisms in both size and structure. Each nanocarrier encapsulates a therapeutic active ingredient, enabling its efficient delivery to the intended site of action.
The technology platform is highly versatile. It is suitable for both clinically established compounds and emerging therapeutic modalities such as RNA- or protein-based agents. The successful implementation of this platform is based on several key components: a flexible manufacturing process that enables the adaptation of nanocarriers to different medical applications, and a design concept that ensures stability, reproducibility and sufficient drug loading capacity.
Through the combination of precise formulation, controlled manufacturing and targeted drug delivery, InnoMedica’s nanotechnology forms the foundation of its clinical development programs — ranging from its therapy for the treatment of Parkinson’s disease to additional applications in oncology and beyond.
